Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Glepaglutide in Short Bowel Syndrome
2017-004394-14Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Aug 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in short bowel syndrome (SBS) comparing Glepaglutide with Placebo (2 arms). Started Aug 2018; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2017-004394-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004394-14.